Stockscreener 앱 받기
47.93
0.81%
-0.39
시간 외 거래:
47.93
전일 마감가:
$48.32
열려 있는:
$48.08
하루 거래량:
1.24M
Relative Volume:
0.52
시가총액:
$117.68B
수익:
$48.62B
순이익/손실:
$6.80B
주가수익비율:
17.09
EPS:
2.8038
순현금흐름:
$7.62B
1주 성능:
-1.28%
1개월 성능:
+0.15%
6개월 성능:
-7.27%
1년 성능:
-5.31%
1일 변동 폭
$47.89
$48.30
1주일 범위
$47.87
$48.75
52주 변동 폭
$45.80
$60.12
사노피 ADR Stock (SNY) Company Profile
SNY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
47.93 | 118.18B | 48.62B | 6.80B | 7.62B | 2.8038 |
|
LLY
Lilly Eli Co
|
762.18 | 717.60B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
164.36 | 377.32B | 90.63B | 22.66B | 18.57B | 9.35 |
|
ABBV
Abbvie Inc
|
184.85 | 338.30B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
114.14 | 234.32B | 55.19B | 13.65B | 16.81B | 6.86 |
|
NVO
Novo Nordisk Adr
|
64.92 | 306.33B | 43.59B | 15.04B | 10.74B | 3.3766 |
사노피 ADR Stock (SNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
| 2025-03-21 | 개시 | Goldman | Neutral |
| 2025-01-30 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-07-26 | 재확인 | Argus | Buy |
| 2024-01-23 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 재개 | UBS | Buy |
| 2023-12-05 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-10-30 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-09-06 | 업그레이드 | Berenberg | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-28 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-03-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-12-13 | 재개 | Morgan Stanley | Overweight |
| 2022-08-12 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-08-09 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-09-27 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | 개시 | Deutsche Bank | Sell |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-03-17 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-03-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-02-11 | 개시 | SVB Leerink | Mkt Perform |
| 2020-01-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-09-20 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | 개시 | Bernstein | Outperform |
| 2019-08-14 | 업그레이드 | UBS | Neutral → Buy |
| 2018-12-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-11-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-09 | 개시 | Guggenheim | Neutral |
| 2018-09-10 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-03-23 | 업그레이드 | Liberum | Hold → Buy |
| 2018-01-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2017-12-06 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2017-08-30 | 업그레이드 | HSBC Securities | Reduce → Hold |
모두보기
사노피 ADR 주식(SNY)의 최신 뉴스
Trogenix Bolsters Clinical Research Team with Appointment of Atif Abbas as Chief Medical Officer and Carolyn Edwards as Vice President, Research & Development - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SanofiSNY - cnhinews.com
Adagene stock gains as Sanofi expands agreement (ADAG:NASDAQ) - Seeking Alpha
SNY’s 2023 Market Dance: Up 3.92% – Time to Invest? - investchronicle.com
Sanofi: Information concerning the total number of voting rights and shares - GlobeNewswire Inc.
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
France’s Sanofi to buy U.S. biopharma group Blueprint for up to $9.5-billion - The Globe and Mail
Sanofi doubles down on immunology with $9.1bn Blueprint deal - Proactive financial news
European ADR Index Slips As Pharma Stocks Buck The Trend - Finimize
Regeneron and Sanofi: Disappointing Top-Line Results for Itepekimab From Two Phase 3 Trials - Morningstar
Regeneron Pharmaceuticals Crashes 19% On A Surprise Sanofi-Tied Failure - Investor's Business Daily
Market movers: Canopy Growth, Zscaler, Regeneron... - Proactive financial news
Regeneron shares plunge after mixed COPD drug trial results - Proactive financial news
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Sanofi: New Anthem from Girl Band Raises Awareness of Type 1 Diabetes After Research Highlights Silent Struggle - Ariva
Prurigo Nodularis Market - GlobeNewswire Inc.
8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.
Dollar Stock Biotech Triples On $470 Million Sanofi Takeover - Investor's Business Daily
Metric Deep Dive: Understanding Sanofi ADR (SNY) Through its Ratios - DWinneX
iRhythm Technologies Inc (IRTC) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
WLK’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com
BIDU’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
A Tale of Resilience: Sanofi ADR Amid Stock Market Turbulence - investchronicle.com
Company’s Banking Stock: Dissecting a 40.08% Quarterly Revenue Decline Amid Growth - investchronicle.com
Trip.com Group Ltd ADR (TCOM) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
CYTK’s 2023 Market Dance: Down -21.41% – Time to Invest? - investchronicle.com
CIG’s Market Whiplash: 8.19% YTD Rise, 9.30% Rise in 30 Days - investchronicle.com
Can Navitas Semiconductor Corp Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
LX’s 2023 Market Dance: Up 43.28% – Time to Invest? - investchronicle.com
Terex Corp (TEX) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Behind Cytosorbents Corp’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com
Procore Technologies Inc (PCOR) Stock: A 52-Week Tale of Drops and Gains - investchronicle.com
Navigating TREE Stock: LendingTree Inc Journey - investchronicle.com
Companhia Siderurgica Nacional ADR (SID) Stock: From Low to High in 52 Weeks - investchronicle.com
The Future of EVgo Inc: Analyzing EVGO - investchronicle.com
Analyzing the Impact of Earnings Reports on Sunstone Hotel Investors Inc Inc. (SHO) Price Performance - investchronicle.com
사노피 ADR (SNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.06%
0.86%
자본화:
|
볼륨(24시간):